A COMPARATIVE STUDY ON EFFICACY AND SAFETY OF TOLPERISONE VERSUS TIZANIDINE IN PATIENTS SUFFERING FROM ACUTE LOW BACK PAIN WITH MUSCLE SPASM by KHAN, ABDUL FAHEEM & PARVEEN, KHANETA
Vol 14, Issue 12, 2021
Online - 2455-3891 
Print - 0974-2441
A COMPARATIVE STUDY ON EFFICACY AND SAFETY OF TOLPERISONE VERSUS TIZANIDINE 
IN PATIENTS SUFFERING FROM ACUTE LOW BACK PAIN WITH MUSCLE SPASM
ABDUL FAHEEM KHAN1, KHANETA PARVEEN2*
1Department of Pharmacology, Chirayu Medical College and Hospital, Bhopal, Madhya Pradesh, India. 2Department of Pathology, Chirayu 
Medical College and Hospital, Bhopal, Madhya Pradesh, India. E-mail: drkhaneta@gmail.com
Received: 03 October 2021, Revised and Accepted: 15 November 2021
ABSTRACT
OBJECTIVES: The objectives of this study were to compare the efficacy and safety of Tolperisone tablets 50 mg three times daily versus Tizanidine 
2 mg tablets thrice daily for the treatment of acute low back pain with muscle spasm.
METHODS: The comparative study was carried out in 50 patients from orthopedics Dr. Pinnamaneni Siddhartha Institute of Medical Sciences 
and Research Foundation, Vijayawada. Only those patients fulfilling the inclusion/exclusion criteria were enrolled into the study. Participants 
suffering from acute low back pain with muscle spasm were divided into two groups. The participants were followed up on Day-14 as final 
analysis.
RESULTS: Subjects receiving Tolperisone showed a mean value of 16.43±1.16 in the Roland Morris low back pain and disability questionnaire both 
groups on day 1 and was reduced to 7.82±1.15 (51.94%) on day 7 and 2.56±1.53 (84.46%) on day 14. Similarly, the patients in the tizanidine group 
had mean value of 15.93±1.61 on day 1, which was reduced to 6.77±1.68 (57.64%) on day 7, and 2.88±1.92 (81.95%) on day 14, as comparable to 
the Tolperisone group. There was no statistically significant difference between the two groups, (p>0.05) for pain at rest, pain at night, restrictions 
of movement, changes in stiffness, changes in numbness, and changes in tenderness. There was a statistically significant difference between the two 
groups, (p<0.05) for pain on movement and kinesalgia.
CONCLUSIONS: Tolperisone was found comparable in efficacy to Tizanidine in improving the clinical symptoms of changes in pain Self-assessment by 
the patient on different applied parameters.
Keywords: Tolperisone, Low back pain, Tizanidine, Muscle spasm.
INTRODUCTION
Acute Low back pain (ALBP) associated with muscle spasm is an 
involuntary, painful contraction of muscles that interferes with the 
function and cause of the muscular disorder. The use of centrally 
acting skeletal muscle relaxants, though efficacious, is associated with 
frequent development of dose-related adverse drug reactions like 
sedation, impairment of voluntary motor functions, and ataxia. Hence, 
there is a need for newer better drugs for the treatment of conditions 
associated with muscle spasm [1,2].
The estimated worldwide lifetime prevalence of low back pain varies 
from 50% to 84%. The occurrence of low back pain in India is also 
alarming with nearly 60% of the people in India have suffered from low 
back pain at some time during their lifespan [2-4].
The current clinical evidence of acute low back pain supports the use of 
centrally acting muscle relaxant alone or in combination with NSAIDs. 
Acute Low back pain (ALBP), a high prevalent condition, is usually 
associated with ‘muscle spasm’ that is giving rise to pain and stiffness. 
Tolperisone hydrochloride, a piperidine derivative, is centrally acting 
muscle relaxant used for treatment muscle spasm associated and pain. 
We also sought to draw a conclusion whether Tolperisone finds its place 
in the treatment of acute LBP and thus aiding the clinicians in choosing 
the appropriate drug for acute LBP associated with muscle spasm [3-5].
Objectives
To compare the efficacy and safety of Tolperisone hydrochloride tablets 
50 mg three times daily versus Tizanidine 2 mg tablets thrice daily for the 
treatment of patients suffering from acute low back pain with muscle spasm.
METHODS
The study was carried in 50 patients from Dr. Pinnamaneni Siddhartha 
Institute of Medical Sciences and Research Foundation (Dr. PSIMS & RF) 
Vijayawada. Only patients satisfying the inclusion criteria were enrolled 
into the study. Potential study subjects were divided during the first visit 
to either of the two groups. The patients were then followed up on day-14.
Clinical diagnosis
Patients suffering from acute low back pain with muscle spasm.
Selection criteria
Inclusion criter ia
Patients in the age group of 18–65 years, patients ready to give informed 
consent, and patients who were clinically stable with precise diagnosis.
Exclusion criteria
Pregnant or Lactating females, childbearing age. Patient with known 
suspected history of hypersensitivity to any of the trial drugs, impaired 
liver function, impaired kidney function, presence of active peptic ulcer 
or any other disease affecting the absorption of drug, hematologic or 
endocrine disorders. Patients already taking or have taken in the past 
the investigational medication. Back pain due to (Acute disc herniation, 
Osteoarthritis or Spinal stenosis, Spondylolisthesis, Ankylosing 
Spondylitis, Infection, and Malignancy).
Study design
Patients were randomly divided into two groups. Each patient as per 
randomization received tolperisone hydrochloride tablets or tizanidine 
tablets daily for a period of 14 days.
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2021v14i12.43295. Journal homepage: https://innovareacademics.in/journals/index.php/ajpcr
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Dosage
Patients randomized into two groups received Tolperisone 50 mg or 
Tizanidine 2 mg per day for a period of 14 days.
Study schedule and plan
The patients were enrolled after informed and written consent as 
per the inclusion and exclusion criteria. Current medical history and 
diagnosis were noted during the first visit. Patient was assigned to 
receive Tolperisone 50 mg or Tizanidine 2 mg. After enrollment into 
study, follow-up was done on day 7. At the initial visit, following the 
general examination, blood sample was withdrawn to estimate Hb, 
RBC, CBC, E.S.R, SGOT, total bilirubin, serum creatinine, and blood sugar 
(fasting). Similar procedure was repeated at the end of the treatment 
i.e., day-7 and day-14.
Administration of “Roland disability questionnaire” at the start 
and end of therapy
This was a 24 point questionnaire and patient was instructed to mark 
the point when your back hurts with pain and mention the severity, 
type, duration, and many more parameters on all the three visits and at 
last, the mean value is calculated from all the three visit and statistics 
applied to observe the significant difference within the group from 
baseline to day 7 and day 14, and also compared between the two 
groups [6-10].
Patients were advised to maintain a “pain diary” which contains the 
different questions related to pain like when did the pain begin? When 
did the pain end, radiating or non-radiating?
The symptoms of back pain were scored based on the ‘Visual Analogue 
Score’ as 0-10 for severity (0-no pain, 1- mild discomfort, 2-moderate 
discomfort, 3-mild pain, 4-mild - moderate pain, 5 – moderate pain, 6– 
moderate – severe pain, 7- severe pain, 8- very severe pain, 9- very very 
severe pain, and 10-agony) [6-12].
Clinical efficacy
The symptoms of back pain were recorded as following parameters 
Pain at rest, Pain at night, Restriction of movement, Pain on movement, 
Stiffness, Numbness, Tenderness, and Kinesalgia. Visual Analogue Score 
from 0 to 10 for severity (0-no pain, 1-mild discomfort, 2-moderate 
discomfort, 3-mild pain, 4-mild - moderate pain, 5-moderate pain, 
6-moderate – severe pain, 7-severe pain, 8-very severe pain, 9-very-very 
severe pain, and 10-agony). Rating Points were given to the patients’ pain 
symptoms according to the severity on each visit and the mean value 
is calculated from each visit and compared to observe the statistically 
significant difference within the group and between the two groups.
Adverse effects if any were recorded in detail. Compliance was evaluated 
by asking the patient to bring balance medicine during follow-up visits. 
A minimum of 80% compliance was taken as satisfactory and only 
those patients with compliance more than 80% were considered for 
efficacy analysis.
The medication was prescribed to the patient and s/he was advised to 
report any adverse event, if any and return for follow-up on the assigned 
days. The patients were also being advised to report any symptomatic 
worsening of the disease.
Assessment of safety
All reported adverse drug reactions in the study population were 
analyzed for their severity, duration, and relation to the study drug.
Statistical analysis
The results were statistically analyzed by students t test, paired t test, 
wilcoxon signed rank test, Mann Whitney test, and Chi-square test.
RESULTS
Demographic Characteristics: Table 1 shows that mean age and average 
weight were comparable There were no dropouts in either group. 
A total of 50 patients (25 in each group) completed the study and were 
included for statistical analysis.
Efficacy parameters
The efficacy parameters were changes in pain Self-assessment by the 
patient and the symptoms of back pain were recorded as following 
parameters Pain at rest, Pain at night, Restriction of movement, Pain 
on movement, Stiffness, Numbness, Tenderness, Kinesalgia. Visual 
analogue score (VAS) from 0 (absent) to 10 (severe) was measured as 
presence or absence.
As seen from Table 2 shows that the patients receiving Tolperisone 
showed a mean value of 16.48±1.15 in the Roland Morris low back 
pain and disability questionnaire both groups on day 1 and was 
reduced to 7.92±1.15 (51.94%) on day 7 and 2.56±1.53 (84.46%) on 
day 14. Similarly, in tizanidine group had mean value of 15.96±1.62 
on day 1, which was reduced to 6.76±1.66 (57.64%) on day 7, and 
2.88±1.92 (81.95%) on day 14, as comparable to Tolperisone group. 
There was no statistically significant difference between the two groups 
but there was statistically significant difference within the two groups 
(p<0.05)*.
Table 3 describes the changes in different pain and stiffness parameters 
between the two groups.
Changes in pain at rest
Pain at rest was reduced from mean value of 2.6±0.57 on day 1 to 
1.24±0.43 (52.30%) after 7 days of administration of Tolperisone, and 
0.12±0.33 (95.38%) after day 14. Similarly, tizanidine reduced the pain 
at rest score from mean value of 3.4±1 on day 1 to 1.88±1.23 (44.70%) 
on day 7, and further 0.68±1.06 (80.0%) on day 14 (p>0.05). There was 
no statistical significant difference between the two groups, (p>0.05), 
but there was statistical significant difference within the two groups 
(p<0.05)*.
Changes in pain at night
In patients receiving Tolperisone, with a mean of 3.12±0.72 showed 
pain at night on day 1. Further, 0.8±0.91 (74.35%) showed improvement 
in pain at night on day 7, and 0.04±0.2 (98.71%) improvement on Day 
14, In patients receiving tizanidine, 3.04±0.73 showed pain at night 
on day 1, followed by 0.56±0.76 (81.57%) improvement on day 7, and 
Table 2: Comparison of changes in pain self-assessment by 
Roland Morris low back pain and disability questionnaire in 
both groups
Duration in days Tolperisone Tizanidine
Basal 16.48±1.15 15.96±1.62
Day 7 7.92±1.15 (51.94%)* 6.76±1.66 (57.64%)* 
Day 14 2.56±1.53 (84.46%) 2.88±1.92 (81.95%)
p>0.05 there was no statistically Significant difference between the two groups. 
*p<0.05 there was statistically significant difference within the two groups
Parameters Tolperisone Tizanidine






















p>0.05 there was no statistically Significant difference between the two groups
Table 1: Demographic profile
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0.12±0.33 (96.05%) improvement on day 14. There was no statistical 
significant difference between the two groups, (p>0.05), but there was 
statistical significant difference within the two groups (p<0.05)*.
Changes in restriction of movement
In patients receiving Tolperisone, with a mean of 3.8±0.5 
showed restriction of movement on Day 1. Further, with a mean 
1.8±0.64 (52.63%) showed improvement in restriction of movement 
on day 7, and 0.56±0.58 (85.26%) on day 14, In patients receiving 
tizanidine, with a mean of 4.32±0.9 showed restriction of movement 
on Day 1, followed by 2.36±1.03 (45.37%) improvement on Day 7, and 
0.84±0.94 (80.55%) on Day 14. There was no statistical significant 
difference between the two groups, (p>0.05), but there was statistical 
significant difference within the two groups (p<0.05)*.
Changes in pain of movement
In patients receiving Tolperisone, with a mean of 3.96±0.351 show 
pain of movement on day 1. Further, 1.72±0.45 (56.56%) showed 
improvement in pain of movement on day 7, and 0.48±0.50 (87.87%) 
on Day 14. In patients receiving tizanidine, 4.72±1.17 show pain of 
movement on Day 1, followed by 2.44±1.26 (48.30%) improvement 
on day 7, and 0.84±1.17 (82.20%) improvement on day 14. There was 
statistical significant difference between the two groups, (p<0.05), and 
also there was statistical significant difference within the two groups 
(p<0.05)*.
Changes in stiffness
In patients receiving Tolperisone, with a mean value of 3.92±0.4 showed 
stiffness on Day 1. Further, 1.84±0.55 (53.06%) showed improvement 
in stiffness on Day 7, and 1.84±0.55 (81.63%) improved on Day 14. 
In patients receiving tizanidine, 4.32±0.80 showed stiffness on Day 1, 
followed by 2.16±0.98 (50.0%) showed improvement on Day 7, and 
0.84±1.028 (80.55%) improved on Day 14. There was no statistically 
significant difference between the two groups, (p>0.05), but there was 
statistical significant difference within the two groups (p<0.05)*.
Changes in numbness
In patients receiving Tolperisone, with a mean of 2.28±0.61 showed 
numbness on Day 1. Further, 1±0.57 (56.14%) showed improvement 
in numbness on Day 7, and 0.2±0.40 (91.22%) improved on day 14. 
In patients receiving tizanidine, 2.6±0.70 showed numbness on day 
1, followed by 1.6±0.70 (38.46%) showed improvement on Day 7, 
and 0.72±0.73 (72.30%) improved on day 14. There was no statistical 
significant difference between the two groups, (p>0.05), but there was 
statistical significant difference within the two groups (p<0.05)*.
Changes in tenderness
In patients receiving Tolperisone, with a mean of 5.28±0.54 
showed tenderness on day 1. Further, 2.6±0.64 (50.75%) showed 
improvement in tenderness on day 7, and 1±0.5 (81.06%) improved 
on day 14. In patients receiving tizanidine, 5.72±0.73 showed 
tenderness on Day 1, followed by 3.04±0.97 (46.85%) showed 
improvement on day 7, and 1.52±1.04 (73.42%) improved on day 
14. There was no statistical significant difference between the two 
groups, (p>0.05), but there was statistical significant difference 
within the two groups (p<0.05)*.
Changes in kinesalgia
In patients receiving Tolperisone, with a mean of 2.36±0.7 showed 
Kinesalgia on day 1. Further, 1.08±0.4 (54.23%) showed improvement 
in Kinesalgia on Day 7, and 0.16±0.37 (93.22%) improved on day 
14. In patients receiving tizanidine, 4±1 showed Kinesalgia on day 1, 
followed by 2.28±1.24 (43.0%) showed improvement on day 7, and 
1.04±1.20 (74.0%) improved on day 14. There was statistical significant 
difference between the two groups, (p<0.05), and also was statistical 
significant difference within the two groups (p<0.05)*.
Table 3: Comparison of different pain and stiffness parameters
Duration in days Tolperisone Tizanidine p value
Changes in pain at rest
Basal 2.6±0.57 3.4±1 p>0.05 between the two groups. *p<0.05 within the two groups
Day 7 1.24±0.43 (52.30%*) 1.88±1.23 (44.70%)* 
Day 14 0.12±0.33 (95.38%) 0.68±1.06 (80.0%)
Changes in pain at night
Basal 3.12±0.72 3.04±0.73 p>0.05 between the two groups. *p<0.05 within the two groups
Day 7 0.8±0.91 (74.35%)* 0.56±0.76 (81.57%)*
Day 14 0.04±0.2 (98.71%) 0.12±0.33 (96.05%)
Changes in restriction of movement
Basal 3.8±0.5 4.32±0.9 p>0.05 between the two groups.*p<0.05 within the two groups
Day 7 1.8±0.64 (52.63%)* 2.36±1.03 (45.37%)*
Day 14 0.56±0.58 (85.26%) 0.84±0.94 (80.55%)
Changes in pain of movement
Basal 3.96±0.35 4.72±1.17 p<0.05 between the two groups. *p<0.05 within the two groups
Day 7 1.72±0.45 (56.56%)* 2.44±1.26 (48.30%)* 
Day 14 0.48±0.50 (87.87%) 0.84±1.17 (82.20%)
Changes in stiffness
Basal 4.32±0.80 3.92±0.4 p>0.05 between the two groups. *p<0.05 within the two groups
Day 7 2.16±0.98 (50.0%) 1.84±0.55 (53.06%)
Day 14 0.84±1.02 (80.55%)* 0.72±0.54 (81.63%)*
Changes in numbness
Basal 2.28±0.61 2.6±0.70 p>0.05 between the two groups. *p<0.05 within the two groups
Day 7 1±0.57 (56.14%) 1.6±0.70 (38.46%)* 
Day 14 0.2±0.40 (91.22%)* 0.72±0.73 (72.30%)
Changes in tenderness
Basal 5.28±0.54 5.72±0.73 p>0.05 between the two groups.*p<0.05 within the two groups
Day 7 2.6±0.64 (50.75%)* 3.04±0.97 (46.85%) 
Day 14 1±0.5 (81.06%) 1.52±1.04 (73.42%)
Changes in kinesalgia
Basal 2.36±0.7 4±1 p<0.05 between the two groups. *p<0.05 within the two groups
Day 7 1.08±0.4 (54.23%) 2.28±1.24 (43.0%) 
Day 14 0.16±0.37 (93.22%)* 1.04±1.20 (74.0%)*
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Efficacy assessment
According to investigator assessment for efficacy (Table 4) 15 (62.5%) 
of total cases had an “excellent” improvement followed by 09 (37.5%) 
“good” in Tolperisone. In tizanidine group, only 07 (29.16%) of total 
cases had an “excellent” improvement followed by 16 (66.66%) “good” 
and 01 (4.16%) “poor”.
Table 4 as per the patient’s own assessment, 17 (70.83%) of total 
cases was rated “excellent”, 07 (29.16%) “good” and 00 (0%) “poor” 
in Tolperisone. In the tizanidine group 07 (29.16%) of total cases was 
rated “excellent” and 14 (58.33%) as “good” and 03 (12.5%) as “poor.”
Tolerability assessment
According to physicians’ assessment for tolerability (Table 4) 
17 (70.83%) of the total cases had “excellent” safety and 05 (20.83%) 
showed “good” safety and 02 (8.33%) as “poor” in group Tolperisone. 
In the tizanidine group, 05 (20.83%) of total cases was rated “excellent” 
and 14 (58.33%) as “good” and 05 (20.83%) as “poor.”
According to patient’s assessment for tolerability (Table 4), 17 (70.83%) 
of the total cases had “excellent” safety and 05 (20.83%) showed “good” 
safety and 02 (8.33%) as “poor” in group Tolperisone. In the tizanidine 
group, 06 (25.0%) of total cases were rated “excellent” and 11 (45.83%) 
as “good” and 07 (29.16%) as “poor.”
DISCUSSION
The results of five studies (3 RCTs and 2 case series) suggest that 
Tolperisone intervention (7–14 days) may be effective in patients with 
acute LBP compared to placebo/thiocolchicoside/diazepam [3-5] and 
in before and after treatment studies [6,7].
Tolperisone intervention improved both pain and physiological 
measures in acute LBP patients. Treatment with Tolperisone for 
4 weeks in chronic LBP patients also improved the pain; non-significant 
to McKenzie therapy and like tizanidine [8-10].
Regarding safety and tolerability, the incidence of AEs was significantly 
less in acute LBP patients treated with Tolperisone when compared 
to those treated with thiocolchicoside and diazepam. In a placebo-
controlled trial [8], a smaller number of acute LBP patients (n=22) 
experienced AEs in Tolperisone group as compared to placebo (n=29). 
This may be because average consumption of rescue (paracetamol 
500 mg) medication was significantly higher in the placebo group. 
Chronic LBP patients on Tolperisone (16.6%) showed numerically 
less dropouts due to AEs compared to tizanidine (30%), and a better 
adherence to the therapy [9,10].
Since, the evidence from the present review on the efficacy of Tolperisone 
for acute/chronic LBP is of low to moderate quality due to the small 
number of included studies and short duration, it is therefore difficult 
for us to suggest a definitive conclusion for the role of tolperiosne in 
the treatment of LBP [11,12]. Our results indicate that Tolperisone is 
an effective muscle relaxant drug with similar clinical benefits to that 
of other molecules, such as Tizanidine, which are currently used in 
the management of acute low back pain due to a contraction of spinal 
muscles. Tolperisone is a muscle relaxant compound with a pattern of 
activities slightly different from that of Tizanidine [11-13].
Limitations of the study
The present study reveals that Tolperisone may be effective in improving 
pain and physiological outcomes in acute LBP patients. However, due to 
a small number of patients, more well-designed RCTs of good quality 
with a larger sample size and longer follow-up period are needed to 
confirm the clinical benefits of Tolperisone in the treatment of acute or 
chronic LBP with or without spasm.
CONCLUSIONS
Tolperisone was found to be comparable to Tizanidine in improving 
symptoms of changes in pain Self-assessment by the patient on 
different applied parameters. The compliance of Tolperisone was found 
to be satisfactory. The global assessment for efficacy and safety for 
Tolperisone was found comparable to tizanidine.
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Table 4: Efficacy and tolerability by physicians and patients
Tolperisone Tizanidine p value
n % n %
Overall assessment of efficacy of treatment by physicians
Excellent 15 62.5 07 29.16 p>0.05, between the two groups.
Good 09 37.5 16 66.66
Poor 00 00 01 4.16
Total 24 100 24 100
Overall assessment of efficacy of treatment by patients
Excellent 17 70.83 07 29.16 p<0.05, between the two groups.
Good 07 29.16 14 58.33
Poor 00 00 03 12.5
Total 24 100 24 100
Overall assessment of tolerability of treatment by physicians
Excellent 17 70.83 05 20.83 p<0.05, between the two groups.
Good 05 20.83 14 58.33
Poor 02 8.33 05 20.83
Total 24 100 24 100
Overall assessment of tolerability of treatment by patients
Excellent 17 70.83 06 25.0 p<0.05, between the two groups.
Good 05 20.83 11 45.83
Poor 02 8.33 07 29.16
Total 24 100 24 100
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